MedTrace Logo

Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

NCT03633630 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-11-08

No results posted yet for this study

Summary

Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Amla

Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days

DRUG

Placebo

Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Esperanza Martínez-Abundis, PhD · Institute of Experimental and Clinical Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-10-30
Completion
2022-03-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633630 on ClinicalTrials.gov